Document:

Form of Restricted Stock Award Agmt.

    EXHIBIT
      10.1

     

     

    
      	
              Your
                Name:
                

            	
            
	
              Total
                No. of Shares: 

            	
              2,500

            

    

    

    CRYOLIFE
      RESTRICTED STOCK AWARD AGREEMENT

    

    CRYOLIFE,
      INC.
      (“CryoLife”) is pleased to grant you the restricted stock award described below
      (“Stock Award”). This grant is made subject to the further terms and conditions
      set forth in this Agreement and the terms of the CryoLife, Inc. 2002 Stock
      Incentive Plan (the “Plan”). 

    

    
      	
              Effective
                Date:

            	
              August
                7, 2006

            
	
              Total
                Number of Shares of Stock Award:

            	
              2,500

            
	
              Vesting:

            	
              Vesting
                occurs at the rate of 1/12 of the Stock

            
	 	
              Award
                on the seventh of each month for a period 

            
	 	
              of
                twelve months from the Effective Date, with the
                

            
	 	
              first
                vesting date occurring on September 7, 2006 and
                

            
	 	
              the
                final vesting date occurring on August 7,
                2007.

            

    

    

    

    The
      following documents accompany this Award Agreement:

    

    Additional
      Terms and Conditions of Your Restricted Stock Award
      describes transferability of your award, what happens if you cease to be a
      member of the CryoLife Board of Directors (the “Board of Directors” or “Board”)
      before all or a portion of your Stock Award vests, where to send notices and
      other matters.

    

    The
      Plan
      contains
      the detailed terms that govern your Stock Award. If
      anything in this Agreement or the other attachments is inconsistent with the
      Plan, the terms of the Plan, as amended from time to time, will control.

    

    The
      Plan Prospectus Document
      covering
      the Stock Award contains important information, including federal income tax
      consequences.

    

    2005
      Annual Report of CryoLife (not
      attached if you previously received the 2005 Annual Report).

    

    Please
      sign below to show that you accept this Stock Award after review of the above
      documents. Keep a copy and return both originals to Suzanne K. Gabbert,
      CryoLife, Inc., 1655 Roberts Blvd., NW, Kennesaw, GA
      30144.

    

    
      	
              CRYOLIFE,
                INC.

            	 	
              GRANTEE:

            	 
	 	 	 	 
	
              By: 
                _______________________________________________

            	 	
            
	
              Name: 
                _____________________________________________

            	 	
              Print
                Your Name: 

            	 __________________________________
	
              Its: 
                _______________________________________________

            	 	
              Date:
                

            	 __________________________________
	
              Date: 
                _____________________________________________

            	 	 	 

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    ADDITIONAL
      TERMS AND CONDITIONS OF YOUR RESTRICTED STOCK AWARD

    

    

    EFFECT
      OF TERMINATION OF SERVICE.
      You
      must
      be a member of the CryoLife Board of Directors on the applicable vesting date
      to
      be entitled to the vesting of your Stock Award on such date. If you cease to
      be
      a member of the CryoLife Board of Directors (including, without limitation,
      by
      reason of death, disability or retirement from the Board), then the portion
      of
      your Stock Award which has not vested as of the date of termination of Board
      service shall automatically be forfeited and cancelled as of the date of such
      termination of Board service.

    

    STOCK
      AWARD SHARE CERTIFICATES.
      Certificates representing the shares of Common Stock to be issued pursuant
      to
      the Stock Award shall be issued in your name and shall be held in by CryoLife
      until the Stock Award is vested or forfeited as provided herein. Following
      vesting of your Stock Award, upon your written request, CryoLife shall promptly
      deliver to you a certificate or certificates representing the shares as to
      which
      the Stock Award has vested, free of the restrictions described in the following
      section. Your rights in your Stock Award are contingent upon your executing
      and
      returning to the Company a form of stock power with respect to the shares
      subject to your Stock Award.

    

    RIGHTS
      WITH RESPECT TO STOCK AWARD PRIOR TO VESTING.
      You may
      not transfer your Stock Award or the shares to be issued hereunder prior to
      vesting. Once this Stock Award vests, you may receive transferable certificates
      representing the vested portion. Prior to vesting, you are entitled to all
      other
      rights as a shareholder with respect to the shares underlying the Stock Award,
      including the right to vote such shares and to receive dividends and other
      distributions, if any, payable with respect to such shares after the date of
      grant. 

    

    NOTICES.
      All
      notices delivered pursuant to this Agreement shall be in writing and shall
      be
      (i) delivered by hand, (ii) mailed by United States certified mail, return
      receipt requested, postage prepaid, (iii) sent by an internationally recognized
      courier which maintains evidence of delivery and receipt, (iv) sent by fax
      to
      (770) 590-3754 , or (v) sent by email to gabbert.suzanne@cryolife.com. All
      notices or other communications shall be directed to the following addresses
      (or
      to such other addresses as such parties may designate by notice to the other
      parties):

    

    
      	
              To
                CryoLife:

            	
              CryoLife,
                Inc.

            
	 	
              1655
                Roberts Blvd., NW 

            
	 	
              Kennesaw,
                GA 30144

            
	 	
              Attention:
                Secretary

            
	 	 
	
              To
                you:

            	
              The
                address set forth in the Agreement

            

    

    

    MISCELLANEOUS.
      Failure
      by you or CryoLife at any time or times to require performance by the other
      of
      any provisions in your Restricted Stock Award Agreement (“Agreement”) will not
      affect the right to enforce those provisions. Any waiver by you or CryoLife
      of
      any condition or of any breach of any term or provision in this Agreement,
      whether by conduct or otherwise, in any one or more instances, shall apply
      only
      to that instance and will not be deemed to waive conditions or breaches in
      the
      future. If any court of competent jurisdiction holds that any term or provision
      of this Agreement is invalid or unenforceable, the remaining terms and
      provisions will continue in full force and effect, and this Agreement shall
      be
      deemed to be amended automatically to exclude the offending provision. This
      Agreement may be executed in multiple copies and each executed copy shall be
      an
      original of this Agreement. This
      Agreement shall be subject to and governed by the laws of the State of
      Georgia. No
      change
      or modification of this Agreement shall be valid unless it is in writing and
      signed by the party against which enforcement is sought, except where
      specifically provided to the contrary herein. This
      Agreement shall be binding upon, and inure to the benefit of, the permitted
      successors, assigns, heirs, executors and legal representatives of the parties
      hereto. The
      headings of each section of this Agreement are for convenience only. This
      Agreement, together with the Plan, contains the entire Agreement of the parties
      hereto, and no representation, inducement, promise, or agreement or other
      similar understanding between the parties not embodied herein shall be of any
      force or effect, and no party will be liable or bound in any manner for any
      warranty, representation, or covenant except as specifically set forth herein
      or
      in the Plan.

     

     

    
      
        
        

      

      
        2exv4w4

 

EXHIBIT 4.4

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED BY THE HOLDER HEREOF FOR ITS OWN ACCOUNT
FOR INVESTMENT WITH NO INTENTION OF MAKING OR CAUSING TO BE MADE A PUBLIC DISTRIBUTION OF ALL OR
ANY PORTION THEREOF. SUCH SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR
ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED, EXCEPT
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER SUCH ACT OR PURSUANT TO AN EXEMPTION
FROM REGISTRATION UNDER SUCH ACT.

Amended Warrant to Purchase

Shares of Common Stock

ARTES MEDICAL, INC.

AMENDED COMMON STOCK PURCHASE WARRANT

Void after June 7, 2009

     Artes Medical, Inc., a Delaware corporation (the “Company”), hereby certifies that, for value
received, Christopher Reinhard (including any successors and assigns, “Holder”), is entitled,
immediately upon or after the date hereof, and subject to the terms set forth below, to purchase
from the Company at any time or from time to time before the earlier of (i) 5:00 PM Pacific time,
on June 7, 2009 or (ii) the closing of (a) the sale, lease, transfer or conveyance of all or
substantially all of the assets of the Company or (b) a consolidation of the Company with, or
merger of the Company with or into, any person (including any individual, partnership, joint
venture, corporation, trust or group thereof) other than a consolidation or merger by the Company
with a subsidiary of the Company in which the Company is the continuing entity (the earlier to
occur of (i) or (ii), the “Expiration Date”) fully paid and nonassessable shares of the Company’s
Common Stock (the “Warrant Shares”), with the number of the Warrant Shares and the exercise price
of the Warrant Shares to be determined as follows:

     (a) Number of Warrant Shares. This Warrant shall evidence the right of the Holder to
purchase up to Six Hundred Fifty Thousand Warrant Shares.

     (b) Exercise Price. The exercise price per Warrant Share (the “Exercise Price”) shall
be an amount equal to One Dollar Twenty Five Cents (U.S. $1.25) per share, subject to adjustment as
provided herein. If the Company should issue, at any time after the date of this Warrant and prior
to the complete exercise of this Warrant, any shares of Common Stock for a consideration per share
less than $1.25 per share, then the Exercise Price for any shares remaining to be exercised under
this Warrant shall be automatically adjusted to the price equal to the price paid per share for
such Common Stock. If the Company should issue, at any time after the date of this Warrant and
prior to the complete exercise of this Warrant, securities or rights convertible into, or entitling
the holder thereof to receive directly or indirectly, additional shares of Common Stock (“Common
Stock Equivalents”), the provisions of Section 6 shall apply.

 

 

     (c) Character of Warrant Shares. This Warrant shall evidence the right of the Holder
to purchase shares of Common Stock of the Company.

     As used herein the following terms, unless the context otherwise requires, have the following
respective meanings:

     (a) The term “Common Stock” shall mean the Common Stock of the Company.

     (b) The term “Company” includes any entity which shall succeed to or assume the obligations of
the Company hereunder.

     1. Exercise Date; Expiration. Subject to the provisions of Section 5.3, this Warrant
may be exercised by the Holder for up to 500,000 Warrant Shares at any time or from time to time
before the Expiration Date (the “Exercise Period”). This Warrant may be exercised by the Holder for
up to an additional 150,000 Warrant Shares as follows: the additional shares will vest and become
exercisable at the rate of 3,125 Warrant Shares per calendar month beginning June 30, 2004 or, if
earlier, at any time after the Company has received final marketing approval by the U.S. Food and
Drug Administration for its first product; provided, however, that in the event that the Expiration
Date of this Warrant is caused by any of the events listed in subsections (ii)(a) or (ii)(b) of the
first paragraph of this Warrant, this Warrant will become fully vested and fully exercisable for
all additional 150,000 Warrant Shares immediately prior to the occurrence of such event.

     2. Exercise of Warrant; Partial Exercise. This Warrant may be exercised in full by
the Holder by surrender of this Warrant, together with the Holder’s duly executed form of
subscription attached hereto as Schedule 1, to the Company at its principal office, accompanied by
payment, in cash or by certified or official bank check payable to the order of the Company, of the
aggregate exercise price (as determined above) of the number of Warrant Shares to be purchased
hereunder. The exercise of this Warrant pursuant to this Section 2 shall be deemed to have been
effected immediately prior to the close of business on the business day on which this Warrant is
surrendered to the Company as provided in this Section 2, and at such time the person in whose name
any certificate for Warrant Shares shall be issuable upon such exercise shall be deemed to be the
record holder of such Warrant Shares for all purposes. As soon as practicable after the exercise
of this Warrant, the Company at its expense will cause to be issued in the name of and delivered to
the Holder, or as the Holder may direct, a certificate or certificates for the number of fully paid
and nonassessable full shares of Warrant Shares to which the Holder shall be entitled on such
exercise, together with cash, in lieu of any fraction of a share, equal to such fraction of the
current market value of one full Warrant Share as determined in good faith by the Board of
Directors, and, if applicable, a new warrant evidencing the balance of the shares remaining subject
to the Warrant.

     3. Net Issuance.

          3.1 Right to Convert. Holder shall have the right to pay the Exercise Price in cash or by returning to the Company
owned shares of Company Common Stock valued in accordance with subsections 3.3(1), 3.3(2) and
3.3(3) below. In addition to and without limiting the rights of the Holder under the terms of this
Warrant, the Holder shall have the right to convert this Warrant (the “Conversion Right”) into
Warrant Shares as provided in this Section 3

2

 

at any time or from time to time during the Exercise
Period. Upon exercise of the Conversion Right with respect to shares subject to the Warrant (the
“Converted Warrant Shares”), the Company shall deliver to the Holder (without payment by the Holder
of any exercise price or any cash or other consideration) that number of fully paid and
nonassessable Warrant Shares computed using the following formula:

	 	 	 
	X = 

	Y (A - B)	 
	 

	A	 

     Where X = the number of shares of Warrant Shares to be delivered to the holder

                 Y = the number of Converted Warrant Shares

                 A = the fair market value of one Warrant Share on the Conversion Date (as defined below)

                 B = the per share exercise price of the Warrant (as adjusted to the Conversion Date)

No fractional shares shall be issuable upon exercise of the Conversion Right, and if the number of
shares to be issued determined in accordance with the foregoing formula is other than a whole
number, the Company shall pay to the Holder an amount in cash equal to the fair market value of the
resulting fractional share on the Conversion Date (as defined below). Shares issued pursuant to
the Conversion Right shall be treated as if they were issued upon the exercise of the Warrant.

          3.2 Method of Exercise. The Conversion Right may be exercised by the Holder by the
surrender of the Warrant at the principal office of the Company together with a written statement
specifying that the Holder thereby intends to exercise the Conversion Right and indicating the
total number of shares under the Warrant that the Holder is exercising through the Conversion
Right. Such conversion shall be effective upon receipt by the Company of the Warrant together with
the aforesaid written statement, or on such later date as is specified therein (the “Conversion
Date”). Certificates for the shares issuable upon exercise of the Conversion Right shall be
delivered to the Holder promptly following the Conversion Date.

          3.3 Determination of Fair Market Value. For purposes of this Section 3, fair market
value of a Warrant Share on the Conversion Date shall mean:

               (1) If traded on a stock exchange, the fair market value of the Common Stock shall be deemed
to be the average of the closing selling prices of the Common Stock on the stock exchange
determined by the Board to be the primary market for the Common Stock over the ten (10) trading day
period (or such shorter period immediately following the closing of an initial public offering)
ending on the date prior to the Conversion Date, as such prices are officially quoted in the
composite tape of transactions on such exchange;

               (2) If traded over-the-counter, the fair market value of the Common Stock shall be deemed to
be the average of the closing bid prices (or, if such information is available, the closing selling
prices) of the Common Stock over the ten (10) trading day period (or such shorter period
immediately following the closing of an initial public offering) ending on

3

 

the date prior to the
Conversion Date, as such prices are reported by the National Association of Securities Dealers
through its NASDAQ system or any successor system; and

               (3) If there is no public market for the Common Stock, then the fair market value shall be
determined by the Board of Directors of the Company in good faith.

     4. Limit on Rights of the Holder upon Exercise. The Holder acknowledges and agrees
that upon the exercise of this Warrant in full or in part, the following provisions shall apply to
the rights of the Holder as a holder of shares of the Company’s capital stock:

          4.1 Market Stand-Off Agreement. During the period of duration specified by the
Company and an underwriter of Common Stock or other securities of the Company, following the
effective date of a registration statement of the Company filed under the Act, the Holder or any
future transferee will not, to the extent requested by the Company and such underwriter, directly
or indirectly sell, offer to sell, contract to sell (including, without limitation, any short
sale), grant any option to purchase or otherwise transfer or dispose of (other than to transferees
or donees who agree to be similarly bound) any securities of the Company held by it at any time
during such period except shares of capital stock included in such registration; provided,
however, that such agreement shall not exceed one hundred eighty (180) days and shall only
apply to the Company’s initial public offering.

          In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions
with respect to the Common Stock of the Holder or any future transferee (and the shares or
securities of every other person subject to the foregoing restriction) until the end of such
period.

     5. Adjustments to Warrant Shares. The number and kind of Warrant Shares (or any
shares of stock or other securities which may be) issuable upon the exercise of this Warrant and
the exercise price hereunder shall be subject to adjustment from time to time upon the happening of
certain events, as follows:

          5.1 Dividends, Distributions, Stock Splits or Combinations. If the Company shall at
any time or from time to time after the date hereof make or issue, or fix a record date for the
determination of holders of Warrant Shares entitled to receive, a dividend or other distribution
payable in additional shares of common or preferred stock (as the case may be), then and in each
such event the exercise price hereunder then in effect shall be decreased as of the time of such
issuance or, in the event such a record date shall have been fixed, as of the close of
business on such record date, by multiplying the exercise price hereunder then in effect by a
fraction: (a) the numerator of which shall be the total number of Warrant Shares (assuming the
exercise or conversion into Warrant Shares of all outstanding securities of the Company that are
convertible into Warrant Shares and the conversion of all such Warrant Shares into Common Stock)
issued and outstanding immediately prior to the time of issuance or the close of business on such
record date; and (b) the denominator of which shall be the total number of Warrant Shares (assuming
the exercise or conversion into Warrant Shares of all outstanding securities of the Company that
are convertible into Warrant Shares) issued and outstanding immediately after the time of issuance
or the close of business on such record date. If the Company shall at any time subdivide the
outstanding Warrant Shares, or if the Company shall at any time combine the

4

 

outstanding Warrant
Shares, then the exercise price hereunder immediately shall be decreased proportionally (in the
case of a subdivision) or increased proportionally (in the case of a combination). Any such
adjustment shall become effective at the close of business on the date the subdivision or
combination becomes effective.

          5.2 Reclassification or Reorganization. If the Warrant Shares issuable upon the
exercise of this Warrant shall be changed into the same or different number of shares of any class
or classes of stock, whether by capital reorganization, reclassification or otherwise (other than a
subdivision or combination of shares or stock dividend provided for in Section 5.1 above, or a
reorganization, merger, consolidation or sale of assets provided for in Section 5.3 below), then
and in each such event the Holder shall be entitled to receive upon the exercise of this Warrant
the kind and amount of shares of stock and other securities and property receivable upon such
reorganization, reclassification or other change, to which a holder of the number of Warrant Shares
issuable upon the exercise of this Warrant would have received if this Warrant had been exercised
immediately prior to such reorganization, reclassification or other change, all subject to further
adjustment as provided herein.

          5.3 Merger, Consolidation or Sale of Assets. If at any time or from time to time
there shall be a capital reorganization of the Warrant Shares or a merger, consolidation or sale of
all or substantially all of the assets of the Company (other than a subdivision, combination,
reclassification or exchange of shares provided for elsewhere in this Section 5) of the Company,
then as a part of such reorganization, provision shall be made so that the Holder shall thereafter
be entitled to receive upon the exercise of this Warrant, the number of shares of stock or other
securities or property of the Company, resulting from such reorganization, merger, consolidation or
sale, to which a holder of the number of Warrant Shares issuable upon the exercise of this Warrant
would have received if this Warrant had been exercised immediately prior to such reorganization,
merger, consolidation or sale.

          5.4 Notice of Record Dates; Adjustments. In the event of, at any time prior to the
Expiration Date, an initial public offering of securities of the Company registered under the
Securities Act of 1933, as amended, or the consolidation or merger of the Company with or into
another Company (other than a merger solely to effect a reincorporation of the Company into another
state), or the sale or other disposition of all or substantially all the properties and assets of
the Company in its entirety to any other person, the Company shall provide to the Holder twenty
(20) days advance written notice of such public offering, consolidation, merger or sale or other
disposition of the Company’s assets, and this Warrant shall terminate unless exercised prior to the
date such public offering is declared effective by the Securities and Exchange Commission or the
occurrence of such consolidation, merger or sale or other disposition of the Company’s
assets. The Company shall promptly notify the Holder in writing of each adjustment or
readjustment of the exercise price hereunder and the number of Warrant Shares issuable upon the
exercise of this Warrant. Such notice shall state the adjustment or readjustment and show in
reasonable detail the facts on which that adjustment or readjustment is based.

     6. Treatment of Common Stock Equivalents. For purposes of Section (b) on the first
page of this Warrant:

          6.1 The aggregate maximum number of shares of Common Stock deliverable upon conversion,
exchange or exercise (assuming the satisfaction of any conditions to

5

 

convertibility,
exchangeability or exercisability, including, without limitation, the passage of time, but without
taking into account potential antidilution adjustments) of any Common Stock Equivalents and
subsequent conversion, exchange or exercise thereof shall be deemed to have been issued at the time
such securities were issued or such Common Stock Equivalents were issued and for a consideration
equal to the consideration, if any, received by the Company for any such securities and related
Common Stock Equivalents (excluding any cash received on account of accrued interest or accrued
dividends), plus the minimum additional consideration, if any, to be received by the Company
(without taking into account potential antidilution adjustments) upon the conversion, exchange or
exercise of any Common Stock Equivalents (the consideration in each case to be determined in the
manner provided pursuant to this Warrant).

          6.2 In the event of any change in the number of shares of Common Stock deliverable or in the
consideration payable to the Company upon conversion, exchange or exercise of any Common Stock
Equivalents, other than a change resulting from the antidilution provisions thereof, the Exercise
Price, to the extent in any way affected by or computed using such Common Stock Equivalents, shall
be recomputed to reflect such change, but no further adjustment shall be made for the actual
issuance of Common Stock or any payment of such consideration upon the conversion, exchange or
exercise of such Common Stock Equivalents.

          6.3 Upon the termination or expiration of the convertibility, exchangeability or
exercisability of any Common Stock Equivalents, the Exercise Price, to the extent in any way
affected by or computed using such Common Stock Equivalents, shall be recomputed to reflect the
issuance of only the number of shares of Common Stock (and Common Stock Equivalents that remain
convertible, exchangeable or exercisable) actually issued upon the conversion, exchange or exercise
of such Common Stock Equivalents.

     7. Replacement of Warrants. On receipt by the Company of evidence reasonably
satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in
the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity
agreement reasonably satisfactory in form and amount to the Company or, in the case of any such
mutilation, on surrender and cancellation of such Warrant, the Company at its expense will execute
and deliver to the Holder, in lieu thereof, a new Warrant of like tenor.

     8. No Rights or Liability as a Stockholder. This Warrant does not entitle the Holder
hereof to any voting rights or other rights as a stockholder of the Company. No provisions hereof,
in the absence of affirmative action by the Holder to purchase Warrant Shares, and no enumeration
herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder as
a stockholder of the Company.

     9. Miscellaneous.

          9.1 Transfer of Warrant. This Warrant shall not be transferable or assignable in any
manner and no interest shall be pledged or otherwise encumbered by Holder without the express
written consent of the Company, and any such attempted disposition of this Warrant or any portion
hereof shall be of no force or effect unless such disposition is in compliance with the Purchase
Agreement.

6

 

          9.2 Titles and Subtitles. The titles and subtitles used in this Warrant are for
convenience only and are not to be considered in construing or interpreting this Warrant.

          9.3 Notices. Any notice required or permitted under this Warrant shall be given in
writing.

          9.4 Attorneys’ Fees. If any action at law or in equity is necessary to enforce or
interpret the terms of this Warrant, the prevailing party shall be entitled to reasonable
attorneys’ fees, costs and disbursements in addition to any other relief to which such party may be
entitled.

          9.5 Amendments and Waivers. Any term of this Warrant may be amended and the
observance of any term of this Warrant may be waived (either generally or in a particular instance
and either retroactively or prospectively), with the written consent of the Company and the holder
of this Warrant. Any amendment or waiver effected in accordance with this Section 9.5 shall be
binding upon the Holder of this Warrant (and of any securities into which this Warrant is
convertible), each future holder of all such securities, and the Company.

          9.6 Severability. If one or more provisions of this Warrant are held to be
unenforceable under applicable law, such provision shall be excluded from this Warrant and the
balance of the Warrant shall be interpreted as if such provision were so excluded and shall be
enforceable in accordance with its terms.

          9.7 Governing Law. This Warrant shall be governed by and construed and enforced in
accordance with the laws of the State of California, without giving effect to its conflicts of laws
principles.

          9.8 Counterparts. This Warrant may be executed in any number of counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     10. Holder Acknowledgments and Representations. Holder:

          (a) Acknowledges that prior to the date of this Warrant, he has accepted the positions of
director, and Chairman of the Board of Directors, of the Company, and has had the opportunity to
ask questions and receive all information he deems relevant to the Company and this Warrant.

          (b) Understands this Warrant may constitute a “security” under federal and/or state securities
laws, and represents that he is acquiring the Warrant, together with any Common shares of Common
Stock which may be acquired upon exercise of the Warrant, for his own account for investment
purposes, and not with a view to resale or distribution of all or any portion thereof.

          (c) Acknowledges that the Company is an emerging company subject to all the risks inherent in
such companies including, without limitation, a current weak financial condition and no certainty
of a successful product.

7

 

          (d) Confirms that he has been encouraged to consult with personal legal counsel regarding this
Warrant.

     11. Amendment and Restatement of Prior Warrant. The Company and Holder confirm that
the original Common Stock Purchase Warrant issued to Holder on June 7, 2004 (the “Prior Warrant”)
is hereby amended in its entirety and restated herein. Upon execution and delivery of this
Warrant, all of the terms and conditions set forth in this Warrant shall supersede and replace the
terms and conditions set forth in the Prior Warrant, and the Prior Warrant shall have no further
force or effect.

8

 

Date: June 9, 2006

	 	 	 	 	 	 	 
	 	 	ARTES MEDICAL, INC.,

a Delaware corporation	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Peter C. Wulff
	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:
	 	Peter C. Wulff	 	 
	 

	 	Title:
	 	Chief Financial Officer	 	 

[SIGNATURE PAGE TO WARRANT]

9

 

SCHEDULE 1

FORM OF SUBSCRIPTION

(To be signed only on exercise of Warrant)

To: ARTES MEDICAL, INC.

     The undersigned, the holder of the Warrant attached hereto, hereby irrevocably elects to
exercise the purchase rights represented by such Warrant for, and to purchase thereunder,
                    * shares of Common Stock of Artes Medical, Inc., and herewith makes payment of
$                                         therefor, and requests that the certificates for such shares be issued in the name
of, and delivered to                                         , whose address is                                
      .

	 	 	 
	 

	 	 
	 

	 	 
	 

	 	(Signature must conform in all respects to name of
the Holder as specified on the face of the Warrant)
	 
	 	 
	 

	 	 
	 

	 	 
	 

	 	(Print Name)
	 
	 	 
	 

	 	 
	 

	 	 
	 

	 	 
	 

	 	 
	 

	 	(Address)
	Dated:                                         
	 	 

 

			
	*	 	Insert here the number of shares as to which the Warrant is being exercised.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}]]